Author’s response to reviews

Title: Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype

Authors:

Robert C De Lisle (rdelisle@kumc.edu)
Racquel Mueller (rmueller@kumc.edu)
Eileen Roach (eroach@kumc.edu)

Version: 4 Date: 13 September 2010

Author’s response to reviews:

As requested, the manuscript has been revised as follows:

1. At the end of the first paragraph of the Methods section, the following statement has been added:

"All animal work was approved by the Institutional Animal Use and Care Committee, of the University of Kansas Medical Center."

2. In the Competing Interests, the following statement has been added:

"Takeda Pharmaceuticals is distributing the substance lubiprostone investigated in this study."